Cargando…
Safety of combining vascular endothelial growth factor receptor tyrosine-kinase inhibitors with chemotherapy in patients with advanced non–small-cell lung cancer: A PRISMA-compliant meta-analysis
BACKGROUND: Vascular endothelial growth factor receptor-tyrosine kinase inhibitors (VEGFR-TKIs) have been developed for targeted therapies in non–small-cell lung cancer (NSCLC); moreover, some drug-related toxic reactions among cancer patients have been reported. A meta-analysis of randomized contro...
Autores principales: | Lv, Wen-wen, Zhang, Jin-jie, Zhou, Xiao-long, Song, Zheng, Wei, Chuan-mei |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Wolters Kluwer Health
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6571213/ https://www.ncbi.nlm.nih.gov/pubmed/31169681 http://dx.doi.org/10.1097/MD.0000000000015806 |
Ejemplares similares
-
Kanglaite Combined With Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitor Therapy for Stage III/IV Non-Small Cell Lung Cancer: A PRISMA-Compliant Meta-Analysis
por: Kong, Fanming, et al.
Publicado: (2021) -
The association between vascular endothelial growth factor gene polymorphisms and stroke: A PRISMA-compliant meta-analysis
por: Xu, Bingdong, et al.
Publicado: (2019) -
Safety and efficacy of anaplastic lymphoma kinase tyrosine kinase inhibitors in non-small cell lung cancer
por: Wang, Li, et al.
Publicado: (2021) -
Prognostic value of platelet-to-lymphocyte ratio in neoadjuvant chemotherapy for solid tumors: A PRISMA-compliant meta-analysis
por: Long, Yuming, et al.
Publicado: (2021) -
Safety profile of vascular endothelial growth factor receptor tyrosine-kinase inhibitors in pediatrics: a pharmacovigilance disproportionality analysis
por: Xue, Yifei, et al.
Publicado: (2023)